Poly Cystic Ovary SyndromeNCT07419776
The Effect Of Polycystic Ovarian Syndrome Treatment On Ocular Surface.
An observational study of Poly Cystic Ovary Syndrome, run by Cairo University at 1 site in Egypt.
Trial summary
This is a Descriptive prospective cohort study conducted at the Ophthalmology Department in Kasr-Alaini Hospital. A total of 90 subjects, 30 control females with no relevant medical, gynecological or ophthalmic history, and 60 patients with confirmed laboratory and ultrasonography diagnosis of PCOS, were recruited… Read more about this study
- Who is it for?
- Ages 18 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Poly Cystic Ovary Syndrome
- What is being tested?
- dry eye diagnostic system of Mediworks, Optical coherence tomography angiography and Contraceptives, Oral, Combined
- Type of treatment
- Pill or oral medicine, Medical device
- How many people
- 90 participants
- Where
- 1 siteEgypt
- Study dates
- 24 Jun 2023to 20 Nov 2025
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: 90 females, 30 of them with no previous medical or surgical history of importance 60 of them with confirmed laboratory and ultrasonography diagnosis of PCOS; 30 for cocps treatment and 30 for clomiphene citrate.
Who may be able to join
- Females at child bearing period (18-40 years old)
- Patients recently diagnosed with polycystic ovarian syndrome..
Who cannot join
- Patients who were diagnosed with Dry eye disease.
- Patients who were treated with hormonal replacement therapy, Metformin, Aromatase inhibitors, clomiphene citrate or androgen antagonists.
- Patients who underwent ocular surgeries.
- patients with history of diabetes mellitus or hypertension.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect Of Polycystic Ovarian Syndrome Treatment On Ocular Surface
This is a Descriptive prospective cohort study conducted at the Ophthalmology Department in Kasr-Alaini Hospital. A total of 90 subjects, 30 control females with no relevant medical, gynecological or ophthalmic history, and 60 patients with confirmed laboratory and ultrasonography diagnosis of PCOS, were recruited from "Gynecology department in Kasr Alainy hoaspital", firstly PCOS Patients were compared with the control subjects, then the PCOS group subdivided to two subgroups , First group included 30 eyes of 30 females in childbearing period (18-40 years old) scheduled for treatment for non fertility indications with oral contraceptive pills (as a first line of treatment, 2mg Estradiol valerate and 0.5 mg Norgestrel, started on any day between day 1 and 5, given for 21 days and stopped for 7 days, course can be repeated in subsequent cycles), and the second group included 30 eyes of 30 females in childbearing period (18-40 years old) scheduled for treatment with Clomiphene citrate (as a first line of treatment for fertility indications, 50-100 mg on the second to fifth day of the menstrual cycle for 5 days, course can be repeated in subsequent cycles), the two subdivided groups were re-examined 3 and 6 months after treatment . This study granted approval of both ophthalmology and gynecology departments and the approval of Cairo university research ethical committee. Informed consent was obtained from patients who involved in this study.
Inclusion Criteria:
Read more
- Females at child bearing period (18-40 years old)
- Patients recently diagnosed with polycystic ovarian syndrome..
Exclusion Criteria:
- Patients who were diagnosed with Dry eye disease.
- Patients who were treated with hormonal replacement therapy, Metformin, Aromatase inhibitors, clomiphene citrate or androgen antagonists.
- Patients who underwent ocular surgeries.
- patients with history of diabetes mellitus or hypertension.
- Primary outcomes 1- Measuring changes in meibomian glands function, break up time, tear meniscus height, and lipid layer thickness in polycystic ovarian syndrome and with different drugs used in managing it. 2. measuring changes in retinal vessel density and macular thickness.
- Secondary outcome parameters :
- Measuring eye lid margin, conjunctival hyperemia, and ocular surface staining in polycystic ovarian syndrome and with different drugs used in managing it.
- Measuring the central corneal thickness (CCT) changes in polycystic ovarian syndrome and with different drugs used in managing it.
Read the detailed description
Initial Examination:
Patient underwent standard clinical examination and testing including:
- Full history; personal history, history of systemic diseases particularly; diabetes mellitus, hypertension, and history of ocular diseases
- Follicle stimulating hormone (FSH), luteinizing hormone (LH) , free testosterone, fasting insulin, and neutrophil to lymphocyte ratio (NLR) were obtained.
- Standard Patient Evaluation of Eye Dryness Questionnaire (SPEED) in order to quickly track the progression of dry eye symptoms over time.
- Measuring central corneal thickness (CCT) using Corneal pachymetry.
- Corrected visual acuity (using Landolt broken ring visual acuity chart(
- Pupillary light reflex.
- Intra ocular pressure (IOP) measurement (using Goldmann applanation tonometer.(
- Slit lamp examination of the anterior segment.
- Dilated fundus examination (using slit lamp biomicroscopy(
- Primary Assessment for dry eye diseases using Tear breakup time test (TBUT), break up pattern (using Fluorescein Sodium Ophthalmic Strips 0.6 mg) and Schirmer's test (using Schirmer's strips)
- Patient randomly picks one of two covered cards (one of them for right eye and the other for the left), to determine in which eye OCTA will be performed.
- Dry eye diagnostic system device (D130, Medi-Works Precision Instruments; Shanghai, China) was used to assess dry eye. Fig. 29 Corneal pachymetry.
- OCTA macula imaging were performed at the same day after dilatation of patient's pupil 3 times by tropicamide 1% (Mydriacyl® Eye drops, Alcon, Novartis, UK)
- Imaging procedures were performed by the same skilled operator .
- regarding PCOS patients, Imaging, ophthalmic examination, and laboratory tests were repeated at the same eye after 3 and 6 months
- Conditions
- Poly Cystic Ovary Syndrome
- Being tested
- dry eye diagnostic system of Mediworks, Optical coherence tomography angiography, Contraceptives, Oral, Combined, Clomiphene Citrate 50 mg
- Keywords
- Polycystic ovary syndrome, ocular surface, PCOS, oral contraceptive pills, COCPs, clomiphene citrate, Dry eye, OCTA, optical coherence tomography angiography
- Medical subject headings
- Polycystic Ovary Syndrome, Dry Eye Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
dry eye diagnostic system of MediworksDevice
- Dry eye diagnostic system device (D130, Medi-Works Precision Instruments; Shanghai, China) was used to assess dry eye.
- Imaging procedures were performed by the same skilled operator .
- regarding PCOS patients, Imaging, ophthalmic examination, and laboratory tests were repeated at the same eye after 3 and 6 months.
Optical coherence tomography angiographyDevice
- OCTA macula and optic nerve imaging were performed at the same day after dilatation of patient's pupil 3 times by tropicamide 1% (Mydriacyl® Eye drops, Alcon, Novartis, UK)
- Imaging procedures were performed by the same skilled operator .
- regarding PCOS patients, Imaging, ophthalmic examination, and laboratory tests were repeated at the same eye after 3 and 6 months.
Contraceptives, Oral, CombinedDrug
2mg Estradiol valerate and 0.5 mg Norgestrel, started on any day between day 1 and 5, given for 21 days and stopped for 7 days, course can be repeated in subsequent cycles
Clomiphene Citrate 50 mgDrug
as a first line of treatment for fertility indications, 50-100 mg on the second to fifth day of the menstrual cycle for 5 days, course can be repeated in subsequent cycles)
| Study group | Role | What they receive |
|---|---|---|
| Control | 30 control females with no relevant medical, gynecological or ophthalmic history Receives: Device: dry eye diagnostic system of Mediworks; Device: Optical coherence tomography angiography | |
| PCOS group on COCPs | 30 eyes of 30 females in childbearing period (18-40 years old) scheduled for treatment for non fertility indications with oral contraceptive pills (as a first line of treatment, 2mg Estradiol valerate and 0.5 mg Norgestrel, started on any day between day 1 and 5, given for 21 days and stopped for 7 days, course can be repeated in subsequent cycles) Receives: Device: dry eye diagnostic system of Mediworks; Device: Optical coherence tomography angiography; Drug: Contraceptives, Oral, Combined | |
| PCOS group on Clomiphene citrate | 30 eyes of 30 females in childbearing period (18-40 years old) scheduled for treatment with Clomiphene citrate (as a first line of treatment for fertility indications, 50-100 mg on the second to fifth day of the menstrual cycle for 5 days, course can be repeated in subsequent cycles) Receives: Device: dry eye diagnostic system of Mediworks; Device: Optical coherence tomography angiography; Drug: Clomiphene Citrate 50 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measuring changes in Meibomian glands functions in polycystic ovarian syndrome and with different drugs used in managing it.
The meibomian glands loss was analyzed by the dry eye diagnostic system automatically using a built-in infrared lighting system to obtain larger image scope of the meibomian glands, Adjustable depth of field made the glands more prominent and distinguishable against the background, Meibomian glands Loss was graded accordingly
Measured: 6 months
Measuring changes in lipid layer thickness in polycystic ovarian syndrome and with different drugs used in managing it
using dry eye diagnostic system; a white ring projection system to ensure a larger examination area, The recorded lipid layer then was compared with the standard grading template.
Measured: 6 months
Measuring changes in break up time (measured in seconds) in polycystic ovarian syndrome and with different drugs used in managing it [Time Frame: 6 months
using dry eye diagnostic system
Measured: 6 months
Measuring changes tear meniscus height (measured in millimeters) thickness in polycystic ovarian syndrome and with different drugs used in managing it [Time Frame: 6 months
using dry eye diagnostic system
Measured: 6 months
Measuring changes in retinal vessel density in superficial capillary plexus, deep capillary plexus, Foveal avascular zone (measured in percentage) in polycystic ovarian syndrome and with different drugs used in managing it
using OCTA
Measured: 6 months
Measuring changes in macular thickness in superficial capillary plexus, deep capillary plexus and and RNFL thickness around the disc (measured in micrometer) in polycystic ovarian syndrome and with different drugs used in managing it.
using OCTA
Measured: 6 months
Secondary outcomes (5)
Measuring eye lid margin (classified according standard grading template into 4 grades) in polycystic ovarian syndrome and with different drugs used in managing it.
using dry eye diagnostic system
Measured: 6 months
Measuring conjunctival hyperemia (measured as a percentage) in polycystic ovarian syndrome and with different drugs used in managing it.
using dry eye diagnostic system
Measured: 6 months
Measuring ocular surface staining in polycystic ovarian syndrome and with different drugs used in managing it.
using Dry eye diagnostic system; using a built-in yellow filter along with cobalt-blue filter, corneal sodium fluorescein images were obtained, images were classified according to look to: normal, dry spots, pooling, and stagnation.
Measured: 6 months
Measuring changes in choriocapillaris flow area (measured in squared millimeter) in polycystic ovarian syndrome and with different drugs used in managing it.
using OCTA
Measured: 6 months
Measuring the central corneal thickness (CCT) changes in polycystic ovarian syndrome and with different drugs used in managing it
using handheld pachymetry (measured in micrometer)
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2026
- Study start24 Jun 2023
- Primary completion20 Nov 2025
- Study completion20 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Poly Cystic Ovary SyndromeStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 90 participants (actual)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Saad, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07419776
- Sponsor's protocol ID
- MD-404-2022
- Status last verified
- Feb 2026
- First submitted
- 4 Feb 2026
- Last updated
- 19 Feb 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: ll IPD collected throughout the trial
Study at a glance
From the registry record, last updated by the sponsor on 19 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect Of Polycystic Ovarian Syndrome Treatment On Ocular Surface
- ClinicalTrials.gov ID
- NCT07419776
- Acronym / sponsor ID
- MD-404-2022
- Conditions
- Poly Cystic Ovary Syndrome
- Keywords
- Polycystic ovary syndrome, ocular surface, PCOS, oral contraceptive pills, COCPs, clomiphene citrate, Dry eye, OCTA
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 24 Jun 2023 (actual)
- Primary completion
- 20 Nov 2025 (actual)
- Study completion
- 20 Nov 2025 (actual)
- First posted
- 19 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Descriptive prospective cohort study conducted at the Ophthalmology Department in Kasr-Alaini Hospital. A total of 90 subjects, 30 control females with no relevant medical, gynecological or ophthalmic history, and 60 patients with confirmed laboratory and ultrasonography diagnosis of PCOS, were recruited from "Gynecology department in Kasr Alainy hoaspital", firstly PCOS Patients were compared with the control subjects, then the PCOS group subdivided to two subgroups , First group included 30 eyes of 30 females in childbearing period (18-40 years old) scheduled for treatment for non fertility indications with oral contraceptive pills (as a first line of treatment, 2mg Estradiol valerate and 0.5 mg Norgestrel, started on any day between day 1 and 5, given for 21 days and stopped for 7 days, course can be repeated in subsequent cycles), and the second group included 30 eyes of 30 females in childbearing period (18-40 years old) scheduled for treatment with Clomiphene citrate (as a first line of treatment for fertility indications, 50-100 mg on the second to fifth day of the menstrual cycle for 5 days, course can be repeated in subsequent cycles), the two subdivided groups were re-examined 3 and 6 months after treatment . This study granted approval of both ophthalmology and gynecology departments and the approval of Cairo university research ethical committee. Informed consent was obtained from patients who involved in this study.
Inclusion Criteria:
- Females at child bearing period (18-40 years old)
- Patients recently diagnosed with polycystic ovarian syndrome..
Exclusion Criteria:
- Patients who were diagnosed with Dry eye disease.
- Patients who were treated with hormonal replacement therapy, Metformin, Aromatase inhibitors, clomiphene citrate or androgen antagonists.
- Patients who underwent ocular surgeries.
- patients with history of diabetes mellitus or hypertension.
- Primary outcomes 1- Measuring changes in meibomian glands function, break up time, tear meniscus height, and lipid layer thickness in polycystic ovarian syndrome and with different drugs used in managing it. 2. measuring changes in retinal vessel density and macular thickness.
- Secondary outcome parameters :
- Measuring eye lid margin, conjunctival hyperemia, and ocular surface staining in polycystic ovarian syndrome and with different drugs used in managing it.
- Measuring the central corneal thickness (CCT) changes in polycystic ovarian syndrome and with different drugs used in managing it.
Detailed description
Initial Examination:
Patient underwent standard clinical examination and testing including:
- Full history; personal history, history of systemic diseases particularly; diabetes mellitus, hypertension, and history of ocular diseases
- Follicle stimulating hormone (FSH), luteinizing hormone (LH) , free testosterone, fasting insulin, and neutrophil to lymphocyte ratio (NLR) were obtained.
- Standard Patient Evaluation of Eye Dryness Questionnaire (SPEED) in order to quickly track the progression of dry eye symptoms over time.
- Measuring central corneal thickness (CCT) using Corneal pachymetry.
- Corrected visual acuity (using Landolt broken ring visual acuity chart(
- Pupillary light reflex.
- Intra ocular pressure (IOP) measurement (using Goldmann applanation tonometer.(
- Slit lamp examination of the anterior segment.
- Dilated fundus examination (using slit lamp biomicroscopy(
- Primary Assessment for dry eye diseases using Tear breakup time test (TBUT), break up pattern (using Fluorescein Sodium Ophthalmic Strips 0.6 mg) and Schirmer's test (using Schirmer's strips)
- Patient randomly picks one of two covered cards (one of them for right eye and the other for the left), to determine in which eye OCTA will be performed.
- Dry eye diagnostic system device (D130, Medi-Works Precision Instruments; Shanghai, China) was used to assess dry eye. Fig. 29 Corneal pachymetry.
- OCTA macula imaging were performed at the same day after dilatation of patient's pupil 3 times by tropicamide 1% (Mydriacyl® Eye drops, Alcon, Novartis, UK)
- Imaging procedures were performed by the same skilled operator .
- regarding PCOS patients, Imaging, ophthalmic examination, and laboratory tests were repeated at the same eye after 3 and 6 months
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 6 Months
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control | – | Device: dry eye diagnostic system of Mediworks, Device: Optical coherence tomography angiography30 control females with no relevant medical, gynecological or ophthalmic history |
| PCOS group on COCPs | – | Device: dry eye diagnostic system of Mediworks, Device: Optical coherence tomography angiography, Drug: Contraceptives, Oral, Combined30 eyes of 30 females in childbearing period (18-40 years old) scheduled for treatment for non fertility indications with oral contraceptive pills (as a first line of treatment, 2mg Estradiol valerate and 0.5 mg Norgestrel, started on any day between day 1 and 5, given for 21 days and stopped for 7 days, course can be repeated in subsequent cycles) |
| PCOS group on Clomiphene citrate | – | Device: dry eye diagnostic system of Mediworks, Device: Optical coherence tomography angiography, Drug: Clomiphene Citrate 50 mg30 eyes of 30 females in childbearing period (18-40 years old) scheduled for treatment with Clomiphene citrate (as a first line of treatment for fertility indications, 50-100 mg on the second to fifth day of the menstrual cycle for 5 days, course can be repeated in subsequent cycles) |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- 90 females, 30 of them with no previous medical or surgical history of importance 60 of them with confirmed laboratory and ultrasonography diagnosis of PCOS; 30 for cocps treatment and 30 for clomiphene citrate.
Key inclusion criteria (2 listed)
- Females at child bearing period (18-40 years old)
- Patients recently diagnosed with polycystic ovarian syndrome..
Key exclusion criteria (4 listed)
- Patients who were diagnosed with Dry eye disease.
- Patients who were treated with hormonal replacement therapy, Metformin, Aromatase inhibitors, clomiphene citrate or androgen antagonists.
- Patients who underwent ocular surgeries.
- patients with history of diabetes mellitus or hypertension.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| dry eye diagnostic system of Mediworks* Dry eye diagnostic system device (D130, Medi-Works Precision Instruments; Shanghai, China) was used to assess dry eye. * Imaging procedures were performed by the same skilled operator . * regarding PCOS patients, Imaging, ophthalmic examination, and laboratory tests were repeated at the same eye after 3 and 6 months. | Device | Control, PCOS group on COCPs, PCOS group on Clomiphene citrate |
| Optical coherence tomography angiography* OCTA macula and optic nerve imaging were performed at the same day after dilatation of patient's pupil 3 times by tropicamide 1% (Mydriacyl® Eye drops, Alcon, Novartis, UK) * Imaging procedures were performed by the same skilled operator . * regarding PCOS patients, Imaging, ophthalmic examination, and laboratory tests were repeated at the same eye after 3 and 6 months. | Device | Control, PCOS group on COCPs, PCOS group on Clomiphene citrate |
| Contraceptives, Oral, Combined2mg Estradiol valerate and 0.5 mg Norgestrel, started on any day between day 1 and 5, given for 21 days and stopped for 7 days, course can be repeated in subsequent cycles | Drug | PCOS group on COCPs |
| Clomiphene Citrate 50 mgas a first line of treatment for fertility indications, 50-100 mg on the second to fifth day of the menstrual cycle for 5 days, course can be repeated in subsequent cycles) | Drug | PCOS group on Clomiphene citrate |
Primary outcome
Measuring changes in Meibomian glands functions in polycystic ovarian syndrome and with different drugs used in managing it.
Time frame: 6 months
The meibomian glands loss was analyzed by the dry eye diagnostic system automatically using a built-in infrared lighting system to obtain larger image scope of the meibomian glands, Adjustable depth of field made the glands more prominent and distinguishable against the background, Meibomian glands Loss was graded accordingly
Measuring changes in lipid layer thickness in polycystic ovarian syndrome and with different drugs used in managing it
Time frame: 6 months
using dry eye diagnostic system; a white ring projection system to ensure a larger examination area, The recorded lipid layer then was compared with the standard grading template.
Measuring changes in break up time (measured in seconds) in polycystic ovarian syndrome and with different drugs used in managing it [Time Frame: 6 months
Time frame: 6 months
using dry eye diagnostic system
Measuring changes tear meniscus height (measured in millimeters) thickness in polycystic ovarian syndrome and with different drugs used in managing it [Time Frame: 6 months
Time frame: 6 months
using dry eye diagnostic system
Measuring changes in retinal vessel density in superficial capillary plexus, deep capillary plexus, Foveal avascular zone (measured in percentage) in polycystic ovarian syndrome and with different drugs used in managing it
Time frame: 6 months
using OCTA
Measuring changes in macular thickness in superficial capillary plexus, deep capillary plexus and and RNFL thickness around the disc (measured in micrometer) in polycystic ovarian syndrome and with different drugs used in managing it.
Time frame: 6 months
using OCTA
5 secondary outcomes
Measuring eye lid margin (classified according standard grading template into 4 grades) in polycystic ovarian syndrome and with different drugs used in managing it.
Time frame: 6 months
Measuring conjunctival hyperemia (measured as a percentage) in polycystic ovarian syndrome and with different drugs used in managing it.
Time frame: 6 months
Measuring ocular surface staining in polycystic ovarian syndrome and with different drugs used in managing it.
Time frame: 6 months
Measuring changes in choriocapillaris flow area (measured in squared millimeter) in polycystic ovarian syndrome and with different drugs used in managing it.
Time frame: 6 months
Measuring the central corneal thickness (CCT) changes in polycystic ovarian syndrome and with different drugs used in managing it
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Feb 2026.
- Association Between Dry Eye and Polycystic Ovary Syndrome: Subclinical Inflammation May Be Part of the ProcessLink provided by the sponsor.
- Optical Coherence Tomography Angiography Findings in Polycystic Ovary SyndromeLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. ll IPD collected throughout the trial
Related trials for Poly Cystic Ovary Syndrome
RecruitingPhase 1
Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome
Anovulatory Infertility
Not yet recruiting
High Intensity Interval Training Versus Mat Pilates in Women With PCOS
Polycystic Ovarian Syndrome (PCOS), Quality of Life
Active, not recruiting
Inspiratory Muscle Training for the Management of Polyendocrine Metabolic Ovarian Syndrome
Poly Cystic Ovary Syndrome
RecruitingPhase 1
E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study
Poly Cystic Ovary Syndrome
Not yet recruitingPhase 2/3
Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary Syndrome
Poly Cystic Ovary Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Poly Cystic Ovary Syndrome, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measuring changes in Meibomian glands functions in polycystic ovarian syndrome and with different drugs used in managing it. (time frame: 6 months). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2026.